Methods of treating inflammation using cell adhesion inhibitors

ABSTRACT

Compounds and methods of making them having the following formula are described which bind to selectin receptors and thus modulate the course of inflammation, cancer and related diseases by modulating cell-cell adhesion events: ##STR1## wherein each R 1  is independently H or lower alkyl (1-4C); R 2  is H, OH or lower alkyl (1-4C), or a lipophilic group such as a higher alkyl group (5-15C), alkylaryl or one or more additional saccharide residues; 
     R 3  is a negatively charged moiety including SO 4   2- , PO 4   2- , or related group; 
     Y is H or lower alkyl (1-4C); and 
     X is H or --CHR 4  (CHOR 1 ) 2  CHR 5  OR 1  wherein R 4  and R 5  are each independently H, lower alkyl (1-4C), or taken together result in a five- or six-membered ring optionally containing a heteroatom selected from the group consisting of O, S, and NR 1  ; 
     said five- or six-membered ring optionally substituted with one substituent selected from the group consisting of R 1 , CH 2  OR 1 , OR 1 , OOCR 1 , NR 1   2 , NHCOR 1 , and SR 1  with the proviso that if X represents a hexose substituent R 3  and R 4 , taken together, cannot provide a hexose substituent.

This application is a divisional of U.S. application Ser. No.08/189,630, filed Feb. 1, 1994, now U.S. Pat. No. 5,591,835, whichapplication is a continuation-in-part of U.S. application Ser. No.07/910,709, filed Jun. 29, 1992, now abandoned.

TECHNICAL FIELD

The invention relates to compounds useful in the treatment ofinflammation, allergic reactions, autoimmune diseases, and relatedconditions. More specifically, the invention concerns substitutedlactose that binds to selectin receptors and to pharmaceuticalcompositions containing them. The present invention is also directed tosynthetic methods useful in obtaining these analogs and other lactosederivatives.

BACKGROUND ART

It is now well established that cellular interactions are at least inpart mediated by receptor/ligand interactions. One class of receptors isknown to recognize the peptide sequence "RGD"; other receptors recognizecarbohydrate ligands.

One class of receptors that recognize carbohydrate-based ligandsmediates the adhesion of circulating neutrophils to stimulated vascularendothelium. This is a primary event of the inflammatory response andappears to be involved as well in allergic and autoimmune responses.Several receptors have been implicated in this interaction, including afamily of putative lectins that includes gp90^(MEL) (Leu8), ELAM-1, andGMP-140 (PADGEM) and (Gong, J. -G., et al., Nature (1990) 343:757;Johnston, G. I., et al., Cell (1989) 56:1033; Geoffrey, J. S., andRosen, S. D., J. Cell Biol. (1989) 109:2463; Lasky, L. A., et al., Cell(1989) 56:1045). These lectins have been termed L-SELECTIN, E-SELECTIN,and P-SELECTIN.

E-SELECTIN is perhaps the best characterized of the three selectins. Itis particularly interesting because of its transient expression onendothelial cells in response to IL-1 or TNF (Bevilacqua, M. P., et al.,Science (1989) 247:1160). The time course of this induced expression(2-8 hours) suggests a role for this receptor in initial neutrophilextravasation in response to infection and injury. Furthermore,Bevilacqua et al. (see Bevilacqua, M. P., et al., Proc. Natl. Acad. Sci.USA (1987) 84:9238) have demonstrated that human neutrophils or HL-60cells will adhere to COS cells transfected with a plasmid containing aCDNA encoding for the E-SELECTIN receptor. Information regarding the DNAsequences encoding for endothelial cell-leukocyte adhesion molecules aredisclosed within PCT published application WO90/13300 published Nov. 15,1990.

Recently, several different groups have published papers regarding theligand for E-SELECTIN. Loweet al., (1990) Cell, 63:475-484 reported apositive correlation between the E-SELECTIN dependent adhesion of HL-60cell variants and transfected cell lines, with their expression of thesialyl Lewis x (sLex) oligosaccharide, NeuNAc α2-3-Gal-β1-4(Fucα1-3)-GlcNAc. By transfecting cells with plasmids containing anα(1,3/1,4) fucosyltransferase, they were able to convert non-myeloid COSor CHO lines into sLex-positive cells that bind in an E-SELECTINdependent manner. Attempts to block E-SELECTIN dependent adhesion usinganti-sLex antibodies were uninterpretable due to the agglutination ofthe test cells by the antibody. They concluded that one or more membersof a family of oligosaccharides consisting of sialylated, fucosylated,lactosaminoglycans are the ligands for the lectin domain of E-SELECTIN.Phillips et al., (1990) Science, 250:1130-1132 used antibodies withreported specificity for sLex to inhibit the E-SELECTIN dependentadhesion of HL-60 or LEC11 CHO cells to activated endothelial cells.Liposomes containing difucosylated glycolipids with terminal sLexstructures inhibited adhesion, while those containing nonsialylated Lexstructures were partially inhibitory. Walz et al., (1990) Science,250:1132-1135 were able to inhibit the binding of a E-SELECTIN-IgGchimera to HL-60 cells with a monoclonal antibody directed against sLexor by glycoproteins with the sLex structure, but could not demonstrateinhibition with CD65 or CD15 antibodies. Both groups concluded that thesLex structure is the ligand for E-SELECTIN. U.S. patent applicationSer. No. 07/683,458, filed 11 Apr. 1991 U.S. Pat. No. 5,211,937, issuedMay 18, 1993, assigned to the present assignee and incorporated hereinby reference discloses and claims the foregoing minimum tetrasaccharidestructure and identifies the groups putatively interactive with theELAM-1 receptor.

In contrast to E-SELECTIN, the properties of the ligands that bind toL-SELECTIN and P-SELECTIN are not as well worked out. L-SELECTIN appearsto bind a sialic acid bearing ligand based on neuraminidase treatment ofperipheral lymph node high endothelial venules which inhibits L-SELECTINrecognition. True et al., 1990, J. Cell Biol. 111, 2757-2764. Further,other studies using soluble L-SELECTIN in direct binding/inhibitionassays suggests that certain carbohydrate moieties may be importantligand components including mannose and fucose, particularly whensulfated or phosphorylated. Imai et al., 1990 J. Cell Biol. 111,1225-1232. More recent studies suggest that L-Selectin binds to sialylLewis X. Foxall, C., et al., Cell (1992) 117:895-902.

The ligand to P-SELECTIN is thought to have an epitope related to sialylLewis x. This conclusion is based on studies using antibody with thisspecificity that block P-SELECTIN mediated adhesion of HL-60 cells toactivated platelets or COS cells that express P-SELECTIN. Larsen et al.(1990) Cell 63, 467-474. Other experiments have shown that the adhesionof HL-60 cells to P-SELECTIN transfected cells is blocked by thepentasaccharide isolated from milk that has the Lewis^(x) epitope.Recently, P-Selectin has been shown to bind to sulfatides. Aruffo, A.,et al. (1991) Cell, 67:35-44.

Because of the role of selectins in disease, particularly diseasesinvolving unwanted cell-cell adhesion that occurs throughselectin-ligand binding on defined cell types, the identification andisolation of novel ligands that would permit the regulation of suchselectin-ligand binding is sorely needed.

One of the modes of action of compounds of the invention involvesmodulating cell-cell adhesion events and is thought to be viaselectin-ligand binding. However, it is noteworthy that the additionalbiological mechanism(s) of action which accounts for the myriad medicalactivities of compounds of the invention, and derivatives and saltsthereof, is not known.

OBJECTS OF THE INVENTION

The invention provides agonists and antagonists which bind to selectinreceptors and thus modulate the course of inflammation, cancer andrelated responses by modulating cell-cell adhesion events. In thisaspect, the invention is directed to compounds of the formula: ##STR2##wherein each R¹ is independently H or lower alkyl (1-4C); R² is H, loweralkyl (1-4C), a lipophilic group such as a higher alkyl group (5-15C),alkylaryl or one or more additional saccharide residues;

R³ is a negatively charged moiety including SO4²⁻, PO₄ ²⁻, or relatedgroup;

Y is H, OH or lower alkyl(1-4C); and

X is H or, --CHR⁴ (CHOR¹)₂ CHR⁵ OR¹ wherein R⁴ and R⁵ are eachindependently H, lower alkyl(1-4C), or taken together result in a five-or six-membered ring optionally containing a heteroatom selected fromthe group consisting of O, S, and NR¹ ;

said five- or six-membered ring optionally substituted with onesubstituent selected from the group consisting of R¹, CH₂ OR¹, OR¹,OOCR¹, NR¹ ₂, NHCOR¹, and SR¹ with the proviso that if X represents ahexose substituent R⁴ and R⁵, taken together, cannot provide a hexosesubstituent.

In another aspect, the invention is directed to a method to synthesizelactose derivatives which method comprises contacting an intermediate ofthe formula ##STR3## wherein each R⁶ is independently H, lower alkyl(1-4C), or a protecting group; and

wherein Y¹ is H, OH, OOCR⁶, or SR⁶ ;

wherein at least one R⁶, which is at the position to be substituted, andat most one adjacent R⁶ is H and all other R⁶ s are protecting groups;and

R⁷ is a protecting group, or a lipophilic group such as a higher alkylgroup (5-15C);

with an electrophile-donating moiety to obtain a product wherein theelectrophile is substituted for the H of the OH at the position to besubstituted.

In other aspects, the invention is directed to pharmaceuticalcompositions containing the compounds of formula 1 and to methods oftreating inflammation using these compositions. In other aspects, theinvention is directed to compounds of formula 2 and additionalintermediates in the synthesis of selectin binding ligands or otheruseful lactosyl residue-containing moieties.

FIGURES

FIG. 1 shows the effect of compound 13b on rabbits in the acute lunginjury model.

FIG. 2 shows the effect of compound 31 on rabbits in the acute lunginjury model.

FIG. 3 shows the results of the dose response of compound 13b in thereperfusion assay. The results are expressed as the number ofradiolabelled human neutrophils/mg of dry weight of the heart.

MODES OF CARRYING OUT THE INVENTION

This application is a continuation-in-part of U.S. patent applicationSer. No. 07/910,709 filed Jun. 29, 1992. All patents, patentapplications and publications discussed or cited herein are understoodto be incorporated by reference to the same extent as if each individualpublication or patent application was specifically and individually setforth in its entirety.

The invention provides compounds that are useful in the treatment ofinflammation by virtue of their ability to bind to selectin receptors.For example, the role believed to be played by one of the selectinreceptors, ELAM-1, in mediating inflammation can be described asfollows. Blood vessels are lined with endothelial cells capable ofproducing the ELAM-1 surface receptor. Lymphocytes circulating in thevessel contain on their surfaces carbohydrate ligands capable of bindingto the ELAM-1 receptor. This results in transfer of the lymphocytethrough the vessel wall and into the surrounding tissue. While this mayhave a useful effect in some circumstances, as in cases when thesurrounding tissue is infected, excessive transfer of the lymphocytesthrough the vessel wall and into the tissue may also be excessive andcause unwanted inflammation. While not wishing to be limited by anyparticular theory, it is believed that the compounds of the presentinvention which bind the selectin receptors, antagonize the action ofthe surface ligands on the circulating lymphocytes and thus preventtheir transfer through the blood vessel wall to cause inflammation inthe surrounding tissue.

For certain cancers to spread throughout a patient's body, a process ofcell-cell adhesion, or metatasis, must take place. Specifically, cancercells must migrate from their site of origin and gain access to a bloodvessel to facilitate colonization at distant sites. A critical aspect ofthis process is adhesion of cancer cells to endothelial cells that linethe blood vessel wall, a step prior to migrating into surroundingtissue. This process can be interrupted by the administration ofcompounds of the invention which generally aid in blocking cell-celladhesion. Accordingly, compounds of the invention can be used to retardthe spread of cancer cells that display receptors which adhere to acompound of formula 1 or 2.

Assays to Identify Ligands

In their most general form assays for identifying lactose derivativesthat act as selectin ligands involve contacting the appropriateselectin, L-SELECTIN, E-SELECTIN, or P-SELECTIN, with a putative ligandand measuring its binding properties.

Several assays are available to measure the capacity of a compound tobind to L-SELECTIN, E-SELECTIN, or P-SELECTIN, and such assays are wellknown in the art. For example, both the selectin and the putative ligandmay be in solution for a time sufficient for a complex of the selectionand ligand to form, followed by separating the complex from uncomplexedselectin and ligand, and measuring the amount of complex formed.Alternatively, the amount of uncomplexed selectin or compound could bemeasured.

A second and preferred assay format consists of immobilizing either theselectin or the putative ligand on a solid surface, and forming theselectin-ligand complex thereon by contacting the immobilized reagentwith the non-immobilized reagent. The selectin-ligand complex isseparated from uncomplexed reagents, and the amount of complex formedcan be determined by measuring the amount of the non-immobilized reagentpresent in the complex. For example, the putative ligand can be affixedto a microtiter well, followed by adding the desired selectin to thewell and measuring the amount of selectin bound to the ligand.

A variation of the above assay is to genetically engineer cells toexpress high levels of L-SELECTIN, E-SELECTIN, or P-SELECTIN on theirsurface, and to use the cells in lieu of purified selectin. RadiolabeledCOS cells have been used in this type of assay, and can be transfectedwith cDNA that encodes for L-SELECTIN, E-SELECTIN or P-SELECTIN. Afterthe cells have had a sufficient time to adhere to the ligand coatedmicrotiter well, non-adherent cells are removed and the number ofadherent cells determined. The number of adherent cells reflects thecapacity of the ligand to bind to the selectin.

Representative of the application of this type of assay is theidentification of E-SELECTIN ligands. For example, a complete cDNA forthe ELAM-1 receptor was obtained by PCR starting with total RNA isolatedfrom IL-1 stimulated human umbilical vein endothelium. The resultingcDNA was inserted into the CDM8 plasmid (see Aruffo, A., and Seed, B.,Proc. Natl. Acad. Sci. USA (1987) 84:8573) and the plasmid amplified inE. coli. Plasmid DNA from individual colonies was isolated and used totransfect COS cells. Positive plasmids were selected by their ability togenerate COS cells that support HL-60 cell adhesion. DNA sequencingpositively identified one of these clones as encoding for ELAM-1(Bevilacqua, M. P., et al., Science, (1989) 243:1160; Polte, T., et al.,Nucleic Acids Res. (1990) 18:1083; Hession, C., et al., Proc. Natl.Acad. Sci. USA (1990)87:1673). These publications are incorporatedherein by reference for their disclosure of ELAM-1 and genetic materialcoding for its production. The complete nucleotide sequence of theELAM-1 cDNA and predicted amino acid sequence of the ELAM-1 protein aregiven in the above cited article by Bevilacqua et al., which DNA andamino acid sequences are incorporated herein by reference (see alsopublished PCT patent application WO90/13300 which was published November15, 1990, which is incorporated herein by reference).

A full length cDNA encoding ELAM-1 was obtained by 35 cycles of thepolymerase chain reaction with 1 μg of total RNA extracted from IL-1stimulated human umbilical vein endothelial cells, utilizing primerscomplementary to the untranslated flanking sequences SEQ. ID. NO.: 1 andSEQ. ID. NO.: 2. The 2 Kb insert generated by this method was gelpurified, directionally cloned into the mammalian expression vector,CDM8 that had been modified by the insertion of a Sail site into thepolylinker, and grown in E. coli (MC1061/p3). Plasmids were isolatedfrom individual colonies and used to transfect COS cells. PutativeE-SELECTIN encoding plasmids were selected based on the ability of thesetransfected COS cells to support HL-60 cell adhesion 72 hourspost-transfection.

A positive cDNA whose sequence corresponded to the published sequence ofE-SELECTIN with two nucleic acid substitutions was used in allexperiments. COS cells were transfected with 1 μg of this plasmid DNAper 3.5-5.0×10⁵ cells, with 400 μg/ml DEAE-dextran and 100 μMchloroquine for 4 h, followed by a brief exposure to 10% DMSO in PBS.Cells were metabolically radiolabeled overnight with carrier free ³² PO₄and harvested in PBS supplemented with 0.02% azide and 2 mM EDTA at 72hour post-transfection for use in cell adhesion studies.

E-SELECTIN transfected COS cells produced by the above method may beused to assay for glucuronyl glycolipid ligands. Similarly, COS cellsmay be transfected with cDNAs that encode L-SELECTIN and/or P-SELECTIN.The production and characterization of L-SELECTIN IgG chimera constructshave been previously described by Watson S. R. et al., (1990) J. CellBiol. 110:2221-2229. This chimera contains two complement bindingdomains, consistent with its natural expression. See Watson S. R. etal., (1991) J. Cell Biol. 115:235-243. P-SELECTIN chimera wasconstructed in a similar manner as described by Walz, G., et al (1990)Science 250, 1132-1135, and Aruffo, A. et al. (1991) Cell, 67, 35-44,respectively. The chimeras may be expressed in a suitable host cell, forexample, 293 cells and purified. Protein A affinity chromatography isthe preferred method of purification. E-SELECTIN and P-SELECTIN may beconstructed with truncated complement binding domains to standardize thesize of the chimeras and to facilitate their secretion. A variation ofthe above assay is to genetically engineer cells to express high levelsof L-SELECTIN, E-SELECTIN, or P-SELECTIN on their surface, and to usethe cells in lieu of purified selectin. Radiolabeled COS cells have beenused in this type of assay, and can be transfected with cDNA thatencodes for L-SELECTIN, E-SELECTIN or P-SELECTIN. After the cells havehad a sufficient time to adhere to the ligand coated microtiter well,non-adherent cells are removed and the number of adherent cellsdetermined. The number of adherent cells reflects the capacity of theligand to bind to the selectin.

Thus, any candidate compound of the formula 1 may be verified to bindselectin receptors by a positive result in the foregoing assays. Theseassays provide a simple screen for determining the relativeeffectiveness of the various members of the group consisting ofcompounds of formula 1.

Nontherapeutic Uses of Compounds of Formula 1

In addition to their use in treating or preventing inflammation as isfurther described hereinbelow, the compounds of formula 1 are useful indiagnostic and preparatory procedures both in vitro and in vivo.

Compounds of formula 1 may be conjugated to solid substrates and usedfor the purification of selectin receptor protein from biologicalsamples. This is conducted most conveniently by arranging the coupledsubstrate as an affinity chromatography column and applying a sampleputatively containing the selectin receptor protein to the affinitycolumn under conditions wherein the selectin receptor protein isadsorbed whereas contaminating materials are not. The selectin receptorprotein is then subsequently eluted, for example, by adjusting theeluent solution to contain competing amounts of the compound of formula1 or by adjusting pH or salt parameters. Techniques for affinitypurification are well understood, and routine optimization experimentswill generate the appropriate conditions for conduct of the procedure.

The compounds of formula 1 are also useful as detection reagents todetermine the presence or absence of selectin or relatedcarbohydrate-binding receptor ligands. For use in such diagnosticassays, a biological sample suspected to contain selectin receptorprotein or a receptor protein closely related thereto is treated withthe compound of formula 1 under conditions wherein complexation occursbetween the receptor protein and the formula 1 compound, and theformation of the complex is detected. A wide variety of protocols may beutilized in such procedures, analogous to protocols applied inimmunoassays. Thus, direct assay wherein the amount of complex formed isdirectly measured may be utilized; alternatively, competition assays maybe used wherein labeled selectin receptor protein is supplied alongwith, and in competition with, the biological sample. In some forms ofthe assay, it is convenient to supply the compounds of formula 1 inlabeled form so that the complex is detected directly; in alternateprocedures, the complex may be detected by size separations, secondarylabeling reagents, or other alternate means. Suitable labels are knownin the art, and include radioactive labels, fluorescent labels, enzymelabels, chromogenic labels, or composites of these approaches.

The compounds of formula 1 may also be used as competitive diagnosticreagents to detect the quantity of selectin receptor-binding components,such as surface ligands, in biological fluids. For the conduct of suchassays, the compounds of formula 1 are labeled as described above andmixed with the biological sample and contacted with the appropriatereceptor protein; the diminution of binding of the labeled compound offormula 1 to selectin receptor in the presence of biological sample isthen determined.

The compounds of formula 1 may also be used in imagining studies in vivoto determine the location of selectin receptors in situ. For use in suchassays, the compounds of formula 1 are supplied with labels which can bedetected by in vivo imaging techniques, such as scintigraphic labelsincluding indium 111, technetium 99, iodine 131, and the like.

Techniques for coupling compounds such as those of formula 1 to labels,chromatographic supports, or other moieties useful in employing thecompounds in the relevant procedures are well understood in the art.

Antibodies may also be prepared to the compounds of formula 1 bycoupling these compounds to suitable carriers and administering thecoupled materials to mammalian or other vertebrate subjects in standardimmunization protocols with proper inclusion of adjuvants. Suitableimmunogenic carriers include, for example, Keyhole Limpet Hemocyanin(KLH), tetanus toxoid, various serum albumins such as bovine serumalbumin (BSA) and certain viral proteins such as rotaviral VP6 protein.These coupled materials are then administered in repeated injections tosubjects such as rabbits, rats or mice and antibody titers monitored bystandard immunoassay techniques. The resulting antisera may be used perse or the antibody-secreting cells generated by the immunization may beimmortalized using standard techniques and used as a source ofmonoclonal preparations which are immunoreactive with the compounds offormula 1. The resulting antibodies are useful in assay systems fordetermining the presence and/or amount of the relevant formula 1compound. Such assays are useful in monitoring the circulating levels ofcompounds of formula 1 in therapeutic treatments such as those describedbelow.

Administration in Anti-inflammatory Protocols

The compounds of the invention are administered to a subject in needthereof for prophylactically preventing inflammation or relieving itafter it has begun. "Treating" as used herein means preventing orameliorating inflammation and/or symptoms associated with inflammation.The compounds are preferably administered with a pharmaceuticallyacceptable carrier, the nature of the carrier differing with the mode ofadministration, for example, oral administration, usually using a solidcarrier and I.V. administration using a liquid salt solution carrier.Typically, injectable compositions are prepared as liquid solutions orsuspensions; solid forms suitable for solution in, or suspension in,liquid vehicles prior to injection may also be prepared. The compoundsmay also be emulsified or the active ingredient encapsulated in liposomevehicles.

Suitable vehicles are, for example, water, saline, dextrose, glycerol,ethanol, or the like, and combinations thereof. In addition, if desired,the vehicle may contain minor amounts of auxiliary substances such aswetting or emulsifying agents or pH buffering agents. Actual methods ofpreparing such dosage forms are known, or will be apparent, to thoseskilled in the art. See, for example, Remington's PharmaceuticalSciences, Mack Publishing Company, Easton, Pa., 17th edition, 1985.Formulations may employ a variety of excipients including, for example,pharmaceutical grades of mannitol, lactose, starch, magnesium stearate,sodium saccharin cellulose, magnesium carbonate, and the like. Oralcompositions may be taken in the form of solutions, suspensions,tablets, pills, capsules, sustained release formulations, or powders.Particularly useful is the administration of the subject ligandmolecules directly in transdermal formulations with permeation enhancerssuch as DMSO. Other topical formulations can be administered to treatdermal inflammation. In addition, transmucosal administration may beeffected using penetrants such as bile salts or fusidic acid derivativesoptionally in combination with additional detergent molecules. Theseformulations are useful in the preparation of suppositories, forexample, or nasal sprays. For suppositories, the vehicle compositionwill include traditional binders and carriers, such as polyalkyleneglycols, or triglycerides. Such suppositories may be formed frommixtures containing the active ingredient in the range of about 0.5% toabout 10% (w/w), preferably about 1% to about 2%.

Intranasal formulations will usually include vehicles that neither causeirritation to the nasal mucosa nor significantly disturb ciliaryfunction. Diluents such as water, aqueous saline or other knownsubstances can be employed with the subject invention. The nasalformulations may also contain preservatives such as, but not limited to,chlorobutanol and benzalkonium chloride. A surfactant may be present toenhance absorption of the subject proteins by the nasal mucosa.

Typically, the compositions of the instant invention will contain fromless than 1% to about 95% of the active ingredient, preferably about 10%to about 50%. Preferably, between about 10 mg and 50 mg will beadministered to a child and between about 50 mg and 1000 mg will beadministered to an adult. The frequency of administration will bedetermined by the care given based on patient responsiveness. Othereffective dosages can be readily determined by one of ordinary skill inthe art through routine trials establishing dose response curves.

In determining the dose to be administered, it will be noted that it maynot be desirable to completely block all selectin receptors of aparticular type. In order for a normal healing process to proceed, atleast some of the white blood cells or neutrophils must be brought intothe tissue in the areas where any wound, infection or disease state isoccurring. The amount of the selectin ligands administered as blockingagents must be adjusted carefully based on the particular needs of thepatient while taking into consideration a variety of factors such as thetype of disease that is being treated.

The compounds of the present invention are useful to treat a wide rangeof diseases, for example autoimmune diseases such as rheumatoidarthritis and multiple sclerosis. The compositions of the invention areapplicable to treat any disease state wherein the immune system turnsagainst the body causing the white cells to accumulate in the tissues tothe extent that they cause tissue damage, swelling, inflammation and/orpain.

Reperfusion injury is a major problem in clinical cardiology.Therapeutic agents that reduce leukocyte adherence in ischemicmyocardium can significantly enhance the therapeutic efficacy ofthrombolytic agents. Thrombolytic therapy with agents such as tissueplasminogen activator or streptokinase can relieve coronary arteryobstruction in many patients with severe myocardial ischemia prior toirreversible myocardial cell death. However, many such patients stillsuffer myocardial neurosis despite restoration of blood flow. This"reperfusion injury" is known to be associated with adherence ofleukocytes to vascular endothelium in the ischemic zone, presumably inpart because of activation of platelets and endothelium by thrombin andcytokines that makes them adhesive for leukocytes (Romson et al.,Circulation 67:1016-1023, 1983). These adherent leukocytes can migratethrough the endothelium and ischemic myocardium just as it is beingrescued by restoration of blood flow.

There are a number of other common clinical disorders in which ischemiaand reperfusion results in organ injury mediated by adherence ofleukocytes to vascular surfaces, including strokes; mesenteric andperipheral vascular disease; organ transplantation; and circulatoryshock (in this case many organs might be damaged following restorationof blood flow).

Formulations of the present invention might also be administered toprevent the undesirable after effects of tissue damage resulting fromheart attacks. When a heart attack occurs and the patient has beenrevived, such as by the application of anticoagulants or thrombolytic(e.g., tPA), the endothelial lining where a clot was formed has oftensuffered damage. When the antithrombotic has removed the clot, thedamaged tissue beneath the clot and other damaged tissue in theendothelial lining which has been deprived of oxygen become activated.The activated endothelial cells then synthesize selectin receptors, forexample ELAM-1 receptors, within hours of the cells being damaged. Thereceptors are extended into the blood vessels where they adhere toglycolipid ligand molecules on the surface of white blood cells. Largenumbers of white blood cells are quickly captured and brought into thetissue surrounding the area of activated endothelial cells, resulting ininflammation, swelling and necrosis which thereby decreases thelikelihood of survival of the patient.

In addition to treating patients suffering from the trauma resultingfrom heart attack, patients suffering from actual physical trauma couldbe treated with formulations of the invention in order to relieve theamount of inflammation and swelling which normally result after an areaof the body is subjected to severe trauma. Other conditions treatableusing formulations of the invention include various types of arthritisand adult respiratory distress syndrome. After reading the presentdisclosure, those skilled in the art will recognize other disease statesand/or symptoms which might be treated and/or mitigated by theadministration of formulations of the present invention.

Applications of Compounds of Formula 2

The compounds of formula 2 are intermediates in the preparation ofcompounds which contain a lactosyl unit. Notably, the compounds offormula 2 are useful in the preparation of compounds of formula 1 whoseuse is described hereinabove. In addition to the compounds of formula 1,alternative compounds containing a lactose residue may also be prepared,such as:

4-O-(3-O-carbonymethyl-β-D-galactopyranosyl)-3-O-2R,S)-glyceryl!-D-glucopyranose;

4-O-(3-O-carbonymethyl-β-D-galactopyranosyl)-3-O-2R,S)-2,3-dideoxy-2,3-difluoro-propyl!-D-glucopyranose;

4-O- 3-O-{(1R,S)-1-(carboxy)ethyl}-β-D-galactopyranosyl!-3-O-(2R,S)-glycosyl!-D-glucopyranose;

4-O-3-O-{(1R,S)-1-(carboxy)ethyl}-β-D-galactopyranosyl!-3-O-(α-L-fucopyranosyl)-D-glucopyranose;

4-O- 3-O-(α-Neu5Ac)-β-D-galactopyranosyl!-3-O-(2R,S)-glyceryl!-D-glucopyranose;

4-O- 3-O-(α-Neu5Ac)-β-D-galactopyranosyl!-3-O-(2R,S)-2,3-dideoxy-2,3-difluoro-propyl!-D-glucopyranose.

Multivalent Forms of the Receptor Binding Ligands

The affinity of the ligands of the invention for receptor can beenhanced by providing multiple copies of the ligand in close proximity,preferably using a scaffolding structure that is, for example, providedby a carrier moiety. It has been shown that provision of such multiplevalence structure with optimal spacing between the moieties dramaticallyimproves binding to receptor. For example, Lee, R. et al., Biochem(1984) 23:4255, showed that providing multivalent forms of lactoseinhibited labeled ASOR binding to mammalian hepatocytes much moreeffectively when the lactose was supplied as a multivalent entity; theIC₅₀ dropped from 500 μM for a single valent lactose to 9 for a divalentlactosyl compound to 4 for a trivalent lactosyl compound, and with idealor optimal spacing between the three lactose moieties to 0.007 μM.

The multivalency and spacing can be controlled by selection of asuitable carrier moiety. Such moieties include molecular supports whichcontain a multiplicity of functional groups that can be reacted withfunctional groups associated with the ligands of the invention. Aparticularly preferred approach involves coupling of the lactose-derivedligands of the invention to amino groups of the carrier throughreductive amination. Reductive amination is a particularly convenientway to couple aldehyde moieties to free amino groups by first formingthe Schiff base and then treating the conjugate with a reducing agent,such as a hydride reducing agent. Typically, the amino group-bearingcarrier is mixed with the carbohydrate moiety at about pH 9 and allowedto form the Schiff base; the solvents are typically evaporated andreducing agent is added at high pH to complete the reaction.

Particularly convenient carrier moieties to obtain multivalent forms ofthe invention ligands include proteins and peptides, particularly thosecontaining lysyl residues which have s-amino groups available forbinding. It is also useful to include in the peptide or protein at leastone tyrosine residue, as this offers a convenient site for labeling, forexample with radioactive iodine. A particularly convenient carrier toobtain a trivalent couple is the peptide Lys-Tyr-Lys. Complete reactionof the ligands of the invention with the free amino groups on thispeptide results in a trivalent moiety. Thus, compounds of the inventionof the formula: ##STR4## wherein X, Y, and R¹, and R³ are as definedabove, and illustrate the multivalent compounds of the invention. Ofcourse, a variety of carriers can be used, including proteins such asBSA or HSA, a multiplicity of peptides including, for example,pentapeptides, decapeptides, pentadecapeptides, and the like.Preferably, the peptides or proteins contain the desired number of aminoacid residues having free amino groups in their side chains; however,other functional groups, such as sulfhydryl groups or hydroxyl groupscan also be used to obtain stable linkages. For example, thecarbohydrate ligands of the invention may be oxidized to containcarboxyl groups at the reducing terminus which can then be derivatizedwith either free amino groups to form amides or with hydroxyl groups toform esters.

Preparation of the Compounds of Formula 1

The compounds of the invention of Formula 1 may be synthesized using anintermediate of Formula 2. The intermediate of Formula 2, in oneembodiment, can be prepared directly from D-lactose using standardprocedures. In th,s conversion, D-lactose is converted to theoctaacetate in crystalline form, in over 95% yield in the methoddescribed by Hudson, C., and Kuns, A., J Am Chem Soc (1925) 47:2052. Theoctaacetate is, in turn, converted in more than 90% yield by the methodof Hudson, C. (supra) or of Fischer, E. and Fischer, H., Ber (1910)43:2521 to the corresponding lactosyl bromide, also a crystallinecompound. The protected lactosyl bromide is converted by the method ofJansson, K., et al., J Org Chem (1988) 53:5629, in over 60% yield to thecorresponding acylated trimethylsilyl ethyl lactose, which can bedeprotected by deacylation in quantitative yield to obtain2-(trimethylsilyl)ethyl lactoside, 2-(trimethylsilyl)ethylβ-D-galactopyranosyl-β-D glucopyranoside. Alternative protecting groupsat position 1 of the disaccharide may also be used.

This precursor of the compounds of Formula 2 is of the formula: ##STR5##wherein R⁷ is a protecting group, preferably SE or Bn or a lipophilicgroup such as a higher alkyl group (5-15C), wherein SE represents --CH₂CH₂ SiMe₃ and Bn is benzyl.

Reaction Scheme 1 outlines the formation of one embodiment of thecompounds of Formula 2 from this intermediate, where Bz representsbenzoyl.

In step 1 of the reaction scheme, the protected lactose, e.g., thetrimethylsilyl ethyl derivative, is treated with an excess of2,2-dimethoxypropane and dry camphor sulfonic acid is added to thereaction mixture which is stirred for 2-3 days at about roomtemperature. A suitable base, such as triethylamine is added andstirring continued for 10-20 minutes; the mixture is then concentratedto dryness and the base removed. In the case of benzyl lactoside, themethod employed is that of D. Beith-Halahmi et al., Carbohydr. Res.,(1967) 5:25, wherein benzyl lactoside is boiled for 3-4 hours in a largeexcess of dry acetone containing 4-toluene sulfonic acid. The reactionmixture is worked up using standard procedures to recover the product 6a, b (or 19). This intermediate is then benzoylated under suitableconditions using, for example, benzoyl chloride to obtain theintermediate compound shown in reaction scheme as 7 a, b (or 20).

The intermediate 7 a, b (or 20) may then be further derivatized at thefree hydroxyl at the 3-position of the glucoside residue or thisposition may be protected and the compound deprotected at positions 3and 4 of the galactosyl residue and further derivatized at position 3.Position 4 of the galactosyl residue is relatively unreactive. A typicalscheme for utilization of this key intermediate 7 a, b (or 20) is shownin Reaction Scheme 2A. (In this scheme, Bz is benzoyl (PhCO--) and Bn isbenzyl (PhCH₂ --). ##STR6##

As shown in Reaction Scheme 2A, the intermediate 7a, b (or 20) isconverted in two steps to intermediate 10a, b (or 22) by treatment undersuitable conditions with protected methyl 1-thio-L-fucoside. Thereaction is conducted in a nonaqueous aproctic solvent in the presenceof cupric bromide, tetrabutylammonium bromide and molecular sieve. (S.Sato, et al., Carbohydr. Res. (1986) 155:C6). The resultant compoundshown as 10a, b is then selectively acetylated at position 4 ofD-galactopyranosyl residue by the way of its 3,4-orthoester, accordingto literature procedure, without isolation of the intermediate (R. U.Lemieux and H. Drigwez, J. Amer. Chem. Soc., (1975) 97:4069) to giveintermediate 11a, b (or 23). Sulfation of intermediate 11a, b (or 23)produces intermediate 12a, b (or 24) which is deacylated andhydrogenated to yield the final product 13a, b (or 26), a selectinligand.

In another embodiment of the instant invention, shown in reaction scheme2B, intermediates 11a, b or 23 may be phosphorylated to yieldintermediates 14a, b or c respectively, which upon deacylation andhydrogenation yields the final product 15a, b or c. These compoundswould be expected to act as selectin ligand.

In another embodiment of the instant invention, shown in reaction scheme3, intermediate 29, generated via intermediates 27 and 28 from 19, maybe sulphated or phosphorylated to yield intermediate 30a or b,respectively which upon deacylation and hydrogenation yields the finalproduct 31a or b, respectively. These compounds would be expected to actas a selectin ligand. ##STR7## Compounds of the Invention and PreferredEmbodiments

As used herein, alkyl (1-6C) refers to a saturated straight or branchedchain or cyclic hydrocarbyl residue containing 1-6C; lower alkyl issimilarly defined but containing only 1-4C, higher alkyl is similarlydefined but containing 5-15C.

As used herein, alkylaryl is of the formula (CH₂)_(m) -Ar wherein m is1-10 and Ar is a mono- or bicyclic aromatic residue optionallycontaining one or more heteroatoms. Typical embodiments of Ar includephenyl, naphthyl, quinolyl, pyridyl, pyrimidinyl, benzthiazoyl,benzimidazoyl, and the like.

R⁷ is a protecting group or a lipophilic group suitable for saccharideresidues. Typical protecting groups include benzyl, benzoyl, varioussilylalkyl groups, such as trimethylsilylethyl (SE), and the like, andlipophilic groups such as a higher alkyl group (5-15C) as defined above.

Exemplary compounds of formula 1 of the invention are those wherein R³is SO₄ ²⁻, PO₄ ²⁻, or other similar charged moiety.

Additional exemplary compounds of formula 1 include those wherein X is:

6-methyl-3,4,5-trihydroxypyran-2-yl,

6-acetyl-3,4,5,trihydroxypyran-2-yl,

6-propylamido-3,4,5,trihydroxypyran-2-yl,

6-propylamido-2,3,4-trimethoxypyran-2-yl,

6-ethyl-2,3-dihydroxy-4-methoxypyran-2-yl,

6-N-ethylamino-2-hydroxy-3,4-ethoxypyran-2-yl,

3,4,5-tri-n-propyloxypyran-2-yl,

3,4,5-trihydroxypyran-2-yl,

2,3,4-trimethoxyfuran-2-yl,

2,3-dihydroxy-4-methoxyfuran-2-yl

2-hydroxy-3,4-ethoxyfuran-2-yl,

3,4,5-tri-n-propyloxyfuran-2-yl, and

3,4,5-trihydroxyfuran-2-yl;

or wherein both R⁵ and R⁶ are H and all R¹ in X are H or methyl;

or wherein X is 2,3,4-trihydroxybenzoyl,

or wherein X is H.

Thus, particularly preferred compounds of formula 1 are those whereinall R¹ are H or methyl, Y is H, OH, OCH₃ or OAc; and/or X is --CH₂(CHOH)₃ H, 3,4,5-trihydroxypyran-2-yl,3,4,5-trihydroxy-6-methylpyran-2-yl, 3,4,5-trimethoxypyran-2-yl,3,4,5-trimethoxy-6-methylpyran-2-yl, 3,4,5-trihydroxyfuran-2-yl,3,4,5-trimethoxyfuran-2-yl, 2,3,4-trihydroxybenzoyl, or2,3,4-trihydroxynaphthoyl; and R³ is SO₄ ²⁻, PO₄ ²⁻, or other similarcharged moiety.

Most preferred of the compounds of formula 1 are those wherein all R¹are H, R² is H, or --CH₂ (CH₂)₆ CH₃, Y is H, OR¹, or lower alkyl.

For those compounds of formula 2 which represent intermediates preferredforms are those wherein the protecting groups represented by R⁶ arebenzyl or benzoyl, the protecting group represented by R⁷ istrimethylsilylethyl or benzyl, or a lipophilic group such as a higheralkyl group (5-15C), and wherein Y¹ is H, OR⁶ wherein R⁶ is benzyl orbenzoyl as set forth above, and where the free hydroxyl group(s) is atposition 3 of the glucosyl moiety or positions 3 and 4 of the galactosylmoiety. An additional preferred protecting group for positions 3 and 4of the galactosyl moiety is isopropylidene.

The following examples are intended to illustrate but not to limit theinvention.

EXAMPLE 1 Preparation of 2-(Trimethylsilyl) ethyl2,6-di-O-benzoyl-4-O-(2,6-di-O-benzoyl-3,4-O-isopropylidene-β-D-galactopyranosyl)-β-glucopyranoside(7a)

2-(Trimethylsilyl) ethyl4-O-(3,4-O-isopropylidene-β-D-galactopyranosyl)-β-D-glucopyranoside (K.Jansson et al., J. Org. Chem. (1988) 53:5629-5647; 6.6 g, 13.75 mmol)was dissolved in dry pyridine (120 mL). The mixture was cooled to -45°C. and stirred, while benzoyl chloride (9.07 mL, 77.4 mMol.) was addeddropwise, and stirring was continued for 4 h at -45° C.

T.l.c. (8.5:1.5 toluene-ethyl acetate) revealed the presence of a majorproduct, faster-migrating than the starting acetal. A small proportionof a still faster-migrating product (pentabenzoate) was also revealed byt.l.c. The mixture was poured into ice-water and extracted withdichloromethane. The dichloromethane solution was successively washedwith water, aqueous NaHCO₃, and water, dried (Na₂ SO₄), andconcentrated. The concentrate was applied to a column of silica gel with9:1 toluene-ethyl acetate as the eluent and gave a solid whichcrystallized from methanol to afford 7a (5.2 g, 42.3%), α!_(D) +17.5 (C,1.1, chloroform). ¹³ C NMR (CDCl₃): δ167.16, 166.13, 165.87, 165.83(4×PhCO), 111.23 (C(CH₃)₂), 101.50, 100.24 (C-1, C-1'), 82.57, 77.02(C-3', C-4), 73.65, 73.44, 73.01, 72.96, 72.06, 71.97 (C-5, C-5', C-4',C-3, C-2, C-2'), 67.21 (OCH₂ CH₂ Si), 63.69, 62.72 (C-6, C-6'), 27.62,26.28 C(CH₃)₂ !, and 17.75 (CH₂ CH₂ Si).

EXAMPLE 2 Preparation of Benzyl2,6-di-O-benzoyl-4-O-(2,6-di-O-benzoyl-3,4-O-isopropylidene-β-D-galactopyranosyl)-β-D-glucopyranoside(7b)

A stirred and cooled (-45° C., bath) solution of benzyl4-O-(3,4-O-isopropylidene-β-D-galactopyranosyl)-β-D-glucopyranoside (5g, 10.6 mmol; D. Beith-Halahmi et al., Carbohydr Res. (1967) 5:25) indry pyridine (120 mL), was treated with benzoyl chloride (6 mL, 51.8mmol), dropwise, and the stirring was continued for 4 h at -45° C.T.l.c. (8.5:1.5 toluene-ethyl acetate) revealed the presence of a majorproduct, faster-migrating than the starting acetal. A small proportionof a still faster-migrating product (pentabenzoate) was also revealed byt.l.c. The mixture was poured into ice-water and extracted withdichloromethane. The dichloromethane solution was successively washedwith water, aqueous NaHCO₃, and water, dried (Na₂ SO₄), andconcentrated. The concentrate was then applied to a column of silica geland eluted with 9:1 toluene-ethyl acetate. On concentration, thefractions corresponding to the major product gave a solid residue whichcrystallized from hot methanol to afford 7b (5.53 g, 59%); m.p.159°-161° C.; α!_(D) -4.2° (c, 1.3, chloroform). ¹ H NMR (CDCl₃):δ8.2-7.00 (m, 25H, arom.), 5.36 (t, 1H, J 7.8 Hz, H-2'), 5.30 (dd, 1H, J8.0, and 9.5 Hz, H-2), 4.68 (d, 1H, J 8.0 Hz, H-1'), 4.56 (d, 1H, J 8.1Hz, H-1), 3.94 (dd, 1H, J 8.2 and 9.6 Hz, H-3), 3.75 (dd, 1H, J 8.2 and9.7 Hz, H-4), and 1.65 and 1.35 2s, 3H each, C(CH₃)₂ !; ¹³ C NMR(CDCl₃): δ167.16, 166.17, 165.90, and 165.86 (4×PHCO), 111.86 (C(CH₃)₂),102.10, 99.49 (C-1, C-1'), 82.99(C-4), 77.60 (C-3'), 74.02 (C-4'),73.60, 73.50, 72.66 (C-2, C-2', C-3, C-5, C-5'), 70.73 (PhCH₂), 64.29and 63.20 (C-6, C-6'), and 28.26 and 26.88 (CH₃)₂ C!; positive ionLSIMS: 889.7 (M+H)⁺, 781.6 M-OBn)⁺, negative ion LSIMS: 934.1 (M+NO₂)⁻,1041.1 (M+mNBA)⁻.

EXAMPLE 3 Preparation of Benzyl2,6-di-O-benzoyl-3-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-4-O-(2,6-di-O-benzoyl-3,4-O-isopropylidene-β-D-galactopyranosyl)-β-D-glucopyranoside(9b)

A mixture of compound 7b (4 g, 4.5 mmol), methyl2,3,4-tri-O-benzyl-1-thio-α-L-fucopyranoside 8 (3.6 g, 7.75 mmol) andpowdered 4 A molecular sieves (10 g) in 5:1dichloroethane-N,N-dimethylformamide (120 m L), protected from moisture,was stirred for 2 h at room temperature. Cupric bromide (2 g, 9 mmol)and tetrabutylammonium bromide (0.29 g,0.9 mmol) were added and thestirring was continued for 35 h at room temperature. More of the donor 8(1.2 g, 2.6 mmol, in 14.4 mL of 5:1dichloroethane-N,N-dimethylformamide), cupric bromide (0.67 g, 0.3mmol), and molecular sieves 4 A (2 g) were added, and the stirring wascontinued for 16 h at room temperature. T.l.c. (9:1 toluene-ethylacetate) then showed the presence of a major product, faster-migratingthan 7b; a trace of unchanged 7b was also revealed by t.l.c. The mixturewas filtered (a bed of Celite) and the solids thoroughly washed withchloroform. The filtrate and washings were combined and washed withaqueous NaHCO₃ and water, dried and concentrated. The residue wasapplied to a column of silica gel and eluted with 9.5:0.5 toluene-ethylacetate. Concentration of the fractions corresponding to the majorproduct furnished a solid, which crystallized from ether to afford 9b(3.68 g, 76%), based on reacted 7b. Compound 9b had m.p. 180°-181° C.;α!_(D) -8° (C, 1.1, chloroform). ¹ H NMR (CDCl₃): δ5.48 (dd,1H, J 9.3and 7.9 Hz, H-2'), 5.40 (d, 1H, J 3.8 Hz, H-1 fuc), 5.22 (dd, 1H, J 8.6and 7.3 Hz, H-2), 4.49 d, 1H, J 8.6 Hz, H-1), 4.42 (d, 1H, J 7.9 Hz,H-1'), 3.90 (dd, 1H, J 10.2 and 3.8 Hz, H-2 fuc), 1.49 and 1.35, (s, 1Heach, C(CH₃)₂), and 1.29 (d, 3H, J 6.6 Hz, H-6 fuc); ¹³ C, (CDCl₃):δ166.86-165.22 (4×PhCO), 111.44 C(CH₃)₂ !, 100.84, 99.80 (C-1,C-1'),63.17, 63.01 (C-6,C-6'), 28.35, 26.86 C(CH₃)₂ !, and 17.48 (C-6");positive ion LSIMS: 1197.9 (M-OBn)⁺, negative ion LSIMS: 1350.2(M+NO₂)⁻, 1 457.3 (M+mNBA)⁻.

EXAMPLE 4 Preparation of 2-(Trimethylsilyl) ethyl2,6-di-O-benzoyl-3-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-4-O-(2,6-di-O-benzoyl-3,4-O-isopropylidene-β-D-galactopyranosyl)-β-D-glucopyraoside(9a)

A mixture of compound 7a (5.2 g, 5.78 mmol), compound 8 (4.68 g,10.17mmol) and powdered 4A molecular sieves (6 g), in 5:1dichloroethane-N,N-dimethylformamide (135 mL), protected from moisture,was stirred for 2 h at room temperature. Cupric bromide (2.6 g, 11.7mmol), and tetrabutylammonium bromide (3.77 g, 11.7 mmol) were added,and the stirring was continued for a total of 48 h at room temperature,additional amounts of 8 (2.34 g, 5.09 mmol, in 60 mL of 5:1dichloroethane-N,N-dimethylformamide), cupric bromide (1.3 g, 5.85mmol), tetrabutylammonium bromide (1.9 g, 5.85 mmol) and 4A molecularsieves (3 g) being added after 24 h. T.l.c. (9:1 toluene-ethyl acetate)revealed the presence of a major product, faster-migrating than 7a. Someunreacted 7a was also revealed by t.l.c. After processing as describedfor 7b (to give 9b), followed by column chromatography, compound 9a (6.7g, 88%) was obtained as an amorphous solid; positive ion LSIMS: 1442.6(M+Na)⁺, 1340.8 (M-NaSO₃)⁺, negative LSIMS: 1396.2 (M-Na)⁻.

EXAMPLE 5 Preparation of Benzyl2,6-di-O-benzoyl-3-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-4-O-(2,6-di-O-benzoyl-β-D-galactopyranosyl)-β-D-glucopyranoside(10b)

Compound 9b (1.0 g) in 70% aqueous acetic acid (600 mL), was stirred at85°-90° C., the progress of the reaction being monitored by t.l.c.(4:1toluene-ethyl acetate). After 2.5 h, most of the starting acetal 9b wasconverted into a slower-migrating product. T.l.c. also indicated somecleavage of the α-L-fucosyl linkage, as evidenced by the presence of twoby-products, one of which was marginally faster-migrating than theproduct (tribenzyl fucose), and the other slower-migrating (disaccharideproduct). The acetic acid was evaporated under diminished pressure (˜40°C.), the last traces being removed by co-evaporation with several addedportions of toluene. The residue so obtained was purified in a column ofsilica gel with 9:1 toluene-ethyl acetate as the eluent to give 10b (0.6g, 61.8%), as an amorphous solid. ¹³ C NMR (CDCl₃): δ167.25, 166.80,165.23 (4×PhCO), 100.65, 99.85 (C-1, C-1'), 98.18 (C-1 fuc),79.55, 79.08(C-3, C-4), 75.77, 73.20, 72.97, 70.30 (4×PhCH2), 63.38, 62.33 (C-6,C-6'), and 17.16 (C-6 fuc); positive ion LSIMS: 1263.7 (M+H-2H)⁺, 1157.7(M-OBn)⁺, negative ion LSIMS: 1417.1 (M+mNBA)⁻, 1310.3 (M+NO₂)⁻, 1263.2(M-H)⁻.

EXAMPLE 6 Preparation of 2-(Trimethylsilyl) ethyl2,6-di-O-benzoyl-3-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-4-O-(2,6-di-O-benzoyl-β-D-galactopyranosyl)-β-D-glucopyranoside(10a)

Compound 9a (3 g, 2.3 mmol) was taken in 70% aqueous acetic acid (300mL) and the mixture was heated, with stirring, for 2 h at 85°-90° C.(bath). T.l.c. (4:1 toluene-ethyl acetate) showed the presence of amajor product with chromatographic mobility comparable to that of 10b.Processing as described for 9b (to give 10b ), followed by columnchromatography, gave trisaccharide diol 10a (2.3 g, 79%) as an amorphoussolid; α!_(D) -20.6° (C, 1.1, chloroform). ¹³ C NMR (CDCl₃): δ167.26,166.98, 166.78, 165.04 (4×PhCO), 101.31,100.55 (C-1, C-1'), 98.19 (C-1fuc),79.56, 78.98 (C-3, C-4), 75.75, 73.19, 72.98 (3×PhCH₂), 67.84 (OCH₂CH₂ Si), 63.48, 62.19 (C-6, C-6'), 18.45 (OCH₂ CH₂ Si), and 17.16 (C-6fuc).

EXAMPLE 7 Preparation of Benzyl2,6-di-O-benzoyl-4-O-(4-O-acetyl-2,6-di-O-benzoyl-β-D-galactopyranosyl)-3-O-(23,4-tri-O-benzyl-α-L-fucopyranosyl)-βD-glucopyranoside(11b)

Compound 10b (0.56 g) was dissolved in a mixture of benzene (30 mL) andtriethylorthoacetate (30 mL), containing 4-toluenesulfonic acid (0.15g), and the mixture stirred for 1 h at room temperature. The acid wasneutralized with a little triethylamine, and the mixture evaporated todryness. It was then taken in 80% aqueous acetic acid (50 mL) andstirred for 40 min at room temperature. T.l.c. (4:1 toluene-ethylacetate) showed the presence of a major product,faster-migrating thandiol 10b. The acetic acid was removed under diminished pressure, andseveral portion of toluene were added to, and evaporated from theresidue to furnish 11b (0.56 g, 96.6%) as an amorphous solid, α!_(D)-14.3° (c, 1.1, chloroform). ¹ H NMR (CDCl₃): δ8.20-7.00 (m, 40H,arom.), 5.51 (t, 1H, J 8.0 Hz, H-2'), 5.38 (d, 1H, J 3.8 Hz, H-1 fuc),5.30 (d, 1H, J 3.8 Hz, H-4'), 5.20 (dd, 1H, J 8.1 and 10.0 Hz, H-2),4.62 (d, 1H, J 8.2 Hz, H-1), 4.44 (d, 1H, J 7.9 Hz, H-1'), 1.82 (s, 3H,CH₃ CO, and 1.34 (d, 3H, J 6.4 Hz, H-6 fuc). ¹³ C NMR (CDCl₃): δ170.38(CH₃ CO), 166.15, 165.72, 165.57, 164.56 (4×PhCO), 100.45, 99.23 (C-1,C-1'), 97.54 C-1 fuc), 79.48 (C-3). 77.57 (C-4), 74.08, 72.94, 72.70,70.15 (4×PhCH2), 62.54, 60.78 (C-6, C-6'), 20.59 (CH₃ CO), and 16.88(C-6 fuc); positive ion LSIMS: 1307.1 (M+H)⁺), 1200.8 (M-OBn)⁺, negativeion LSIMS: 1460.9 (M+mNBA)⁻, 1353.6 (M+NO₂)⁻, 1306.8 (M-H)⁻.

EXAMPLE 8 Preparation of 2-(Trimethylsilyl) ethyl2,6-di-O-benzoyl-4-O-(4-O-acetyl-2,6-di-O-benzoyl-β-D-galactopyranosyl)-3-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-β-D-galactopyranoside(11a)

A solution of compound 10a (1.87 g), in a mixture of benzene (50 mL) andtriethyl orthoacetate (50 mL), containing 4-toluenesulfonic acid (0.25g) was stirred for 1 h at room temperature. The acid was thenneutralized with a few drops of triethylamine, and the mixtureevaporated to dryness. The residue was mixed with 80% aqueous aceticacid (100 mL) and the mixture stirred for 40 min at room temperature.Processing as described for 10b (to give 11b), gave the title compound11a (1.86 g,89%); a white amorphous solid; α!_(D) -2.7° (c, 1.1,chloroform). ¹³ C NMR (CDCl₃): δ171.03 (CH₃ CO), 166.78, 166.35, 166.18,165.02 (4×PhCO), 101.27, 101.09 (C-1, C-1'), 98.17 (C-1 fuc), 80.10,78.20 (C-3, C-4), 74.67, 73.54, 73.30 (3×PhCH₂), 67.86 (OCH₂ CH₂ Si),63.31, 61.42 (C-6, C-6'), 21.21 (CH₃ CO), 18.47 (OCH₂ CH₂ Si), and 17.53(C-6 fuc); negative ion LSIMS: 1470.8 (M+mNBA)⁻, 1363.7 (M+NO2)⁻.

EXAMPLE 9 Preparation of Benzyl2,6-di-O-benzoyl-3-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-4-O-(sodium4-O-acetyl-2,6-di-O-benzoyl-β-D-galactopyranosyl3-sulfate)-β-D-glucopyranoside (12b)

A mixture of compound 11b (0.6 g, 0.46 mmol) and sulfur trioxidepyridinecomplex (0.6 g, 6.3 mmol) in dry pyridine (50 mL) was stirred for 2 h at55°-60° C. (bath), and then for 16 h at room temperature. T.l.c. (6:1chloroform-methanol) showed the disappearance of 11b and the presence ofa single slower-migrating product. Methanol (5 mL) was added, and themixture stirred for 15 min (to decompose excess reagent). It was thenconcentrated and purified in a column of silica gel by elution with10:1, followed by 6:1 chloroform-methanol. Upon concentration, thefractions corresponding to the product gave a solid residue, which wasdissolved in 1:1 chloroform-methanol (30 mL) and treated with AmberliteIR 120 (Na⁺) cation-exchange resin, and the mixture stirred for 1 h atroom temperature. It was then filtered and evaporated to dryness to give12b (0.58 g, 89%) as an amorphous solid; α!_(D) -5.1° (C, 1.8, 1:1chloroform-methanol);positive LSIMS: 1433 (M+Na)⁺, 1411.1 (M+H)⁺,negative LSIMS: 1563.9 (M+mNBA)⁻, 1386.7 (M-Na)⁻.

EXAMPLE 10 Preparation of 2-(Trimethylsilyl)ethyl2,6-di-O-benzoyl-3-O-(2,3,4-tri-O-benzyl-α-fucopyranosyl)-4-O-(sodium4-O-acetyl-2,6-di-O-benzoyl-β-D-galactoayranosyl3-sulfate)-β-D-glucopyranoside (12a)

A mixture of compound 11a (0.45 g, 0.39 mmol) and sulfurtrioxide-pyridine complex (0.45 g, 4.7 mmol) in dry pyridine (25 mL) wasstirred for 2 h at 55°-60° C., and then overnight at room temperature.After processing and purification, in a manner similar to the aforedescribed, compound 12a (0.46 g, 95.8% ) was obtained as an amorphoussolid; α!_(D) +2.2° (C,1.5, 1:1 chloroform-methanol); positive ionLSIMS: 1442.6 (M+Na)⁺, 1341.1 (M-NaSO₃)⁻, negative ion LSIMS: 1395.5(M-Na)⁻

EXAMPLE 11 Preparation of O-α-L-fucopyranoayl-(1→3)-O- sodiumβ-D-galactopyranosyl 3-sulfate-(1→4)!-D-glucopyranose (13b).

Compound 12b (0.58 g) in methanol (50 mL), containing a catalytic amountof sodium methoxide, was stirred overnight at 45°-50° . T.l.c. (13:6:1chloroform-methanol-water) showed the presence of a singleslower-migrating product. After cooling to room temperature, AmberliteIR 120 (H⁺) cation-exchange resin was added till the mixture becameneutral (pH paper). It was then filtered directly into a flaskcontaining Amberlite IR 120 (Na⁺) cation-exchange resin, and the mixturestirred for 45 min. It was then concentrated, and the residue repeatedlyextracted with hexane-ether mixture to remove methyl benzoate. Thepartially-protected intermediate so obtained (0.38 g,) was sufficientlypure to be utilized directly in the next step; negative ion LSIMS: 928.1(M-Na)⁻. A portion (0.35 g), without further purification, was taken in80% aqueous methanol (30 mL), containing 10% palladium-on-carbon (0.35g). The mixture was stirred overnight at room temperature under a slightoverpressure of H₂, when t.l.c. (5:4:1, or 13:6:1chloroform-methanol-water) indicated the presence of a slower-migratingproduct, together with traces of some faster-migrating contaminants(presumably due to incomplete hydrogenolysis). The mixture was filtered(Celite bed) directly onto Amberlite IR 120 (Na⁺) cation-exchange resin,and the solids thoroughly washed with aqueous methanol. After stirringwith the resin for 1 h, the mixture was filtered and concentrated to asmall volume, which was applied to a column of silica gel and elutedwith 5:4:1 chloroform-methanol-water. Fractions corresponding to theproduct were pooled, concentrated to a small volume and treated withAmberlite IR 120 (Na⁺) cation-exchange resin. The resin was filtered offand washed with water, and the filtrate and washings combined,refiltered (0.2 μM Cellulose acetate syringe filter), and lyophilized togive 13b, (183 mg, 84.3%; α!_(D) -20.5° (c, 0.6, water). 1H NMR (D₂):δ5.45 d, 1H, J 4.13 Hz, H-1 fuc (β)!, 5.39 d, 1H, J 3.81 Hz, H-1 fuc(α)!, 5.18 (d, 1H, J 3.81 Hz, H-1), 4.66 (d, 1H, J 7.93 Hz, H-1'), 4.55d, 1H, J 7.62 Hz, H-1 (β)!; negative ion LSIMS: 567.5 (M-Na)⁻, 421(M-Na-Fuc)⁻.

EXAMPLE 12 Preparation of 2-(Trimethylsilyl) ethylO-α-L-fucopyranosyl-(1→3)-O- sodium-β-D-galactopyranosyl3-sulfate-(1→4)!-β-D-glucopyranoside (13a)

Compound 12a (0.45 g) was O-deacylated in methanolic sodium methoxide(50 mL), exactly as described for 10, to afford the correspondingpartially benzylated intermediate (0.29 g), which showed positive ionLSIMS: 983.9 (M+Na)⁺, 882.1 (M-NaSO₃), negative ion LSIMS: 938.0(M-Na)⁻.This compound (0.24 g) without any further purification, was subjectedto catalytic hydrogenolysis in 80% aqueous methanol (30 mL) in thepresence of 10% palladium-on-carbon (0.24 g), and then processed in amanner analogous to the afore described to afford compound 13a (125 mg,72.7%), as a white fluffy material; α!_(D) -49.2° (c,0.6. water). ¹ HNMR (D₂ O ): δ5.45 (d, 1H, J 4.22 Hz, H-1 fuc), 4.55 (d,1H, J 8.06 Hz,H-1'),4.49 (d, 1H, J 8,44 Hz,H-1), 4.32 (dd, 1H, J 3.45 and 9.98 Hz,H-3'); positive ion LSIMS: 713.8 (M+Na)⁺, negative ion LSIMS: 667.6(M-Na)⁻.

EXAMPLE 13 Preparation of a Multivalent Ligand, N,6N,6N' Tris (20)Lys-Tyr-Lys

Compound 13a or 13b, prepared in Example 12, may be derivatized to thepeptide Lys-Tyr-Lys to obtain the trivalent conjugate derivatized at thetwo ε-amino lysine groups and the α-amino N-terminal of the peptide. Toobtain this trivalent compound, 50 μl of 2 mM peptide Lys-Tyr-Lys (100nmol) in 100 mM sodium carbonate, pH 9, are placed in a small Eppendorftube containing 5 μl of 200 mM 20 (1 mmol), and the sample is evaporatedto dryness in a SpeedVac for about 30 minutes.

After evaporation, 50 μl of 800 mM NaCN-BH₃ (recrystallized, 40 μmol) in100 mM sodium carbonate, pH 9, is added and the mixture is incubated for48 hours at 55° C. The resulting incubated mixture is run on a GPCpeptide HPLC sizing column and fractions are collected and assayed forprotein content by BCA protein assay. Protein-containing fractions arepooled, lyophilized and submitted for mass spectroscopy.

The results would show the formation of the derivatized peptide ascontaining 1, 2 or 3 moieties of compound 13a or 13b.

The trivalent derivative would be especially effective in inhibiting thebinding of lactose to hepatocytes in an assay conducted as described byLee, R. et al., Biochem (1984) 23:4255.

EXAMPLE 14 Preparation of Octyl4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-2,3,6-tri-O-acetyl-β-Dglucopyranoside(17)

A mixture of n-octanol (20 mL), silver oxide (10 g), and dririte (25 g)in 1:1 benzene-ether (250 mL) was stirred at room temperature, underanhydrous conditions, for 1 h. Acetobromolactose (16, 25 g, 35.7 mmol)was added and the mixture was stirred overnight at room temperature. Thesolids were then filtered off over a celite bed and washed withchloroform. The filtrate was concentrated, hexane (4×50 ml) was added tothe product and decanted from the residue and the crude product waspurified on a silica gel column (3:1 followed by 2:1 hexane-ethylacetate) to yield 17 (15.8 g, 59%), as an amorphous white solid. Ananalytical sample was crystallized from dichloromethane-ether-heptane;m.p. 83°-85° C.; α!_(D) -14.7° (C 1.1 chloroform), t.l.c. (1:1 ethylacetate-hexane). ¹³ C NMR (CDCl₃): δ170.41-169.10 (CH₃ CO), 101.05,100.58 (C-1, C-1'), 76.34 (C-4), 70.21 OCH₂ (CH₂)₆ !, 62.10, 60.85 (C-6,C-6'), 31.79-22.64 (CH₂)₆ CH₃ !, 14.09 (CH₃); negative LSIMS: 901.8(M-H+mNBA)⁻, 747.8 (M-H)⁻, 705.7,663.7, 621.7 (M-Ac, 2Ac, 3Ac,respectively); positive LSIMS: 771.9 (M+Na)⁺

EXAMPLE 15 Preparation of Octyl4-O-β-D-galacopyranosyl-β-D-glucopyranoside (18)

Compound 17 (30 g) was dissolved in dry methanol (150 mL), containing acatalytic amount of sodium methoxide, and the mixture was stirred atroom temperature. In about 30 minutes, crystallization of thedeacetylated material ensued, and the mixture was stirred overnight atroom temperature. The base was neutralized with glacial acetic acid, andthe crystalline material was filtered and washed with a mixture ofmethanol-ethanol and dried in air and then in vacuo to yield 18, (15.2g, 83.5%); m.p. 179°-181° C.; α!_(D) -10.9° (c 1.0, methanol), t.l.c.(13:6:1 chloroform-methanol-water or 3:2:1 ethylacetate-propanol-water). ¹³ C NMR (DMSO-d₆): δ104.20, 102.89 (C-1,C-1'), 81.15 (C-4), 69.10 OCH₂ (CH₂)₆ !, 60.88, 60.77 (C-6, C-6'),31.64-22.48 (CH₂)₆ C₃ !, and 14.34 (CH₃); negative LSIMS: 453.4 (M-H)⁻.An additional amount of 18 (1.6 g) was obtained after deionization andconcentration of the mother liquor (total yield 92%).

EXAMPLE 16 Preparation of Octyl4-O-(3,4-O-isopropylidene-β-D-galactopyranosyl)-β-D-glucopyranoside (19)

Method (a): A Mixture of 18 (5 g) and camphorsulfonic acid (0.2 g) in2,2-dimethoxypropane (200 mL) was stirred for 48 h at room temperature.The acid was neutralized with triethylamine and the mixtureconcentrated. The residue was mixed with toluene and evaporated toremove traces of triethylamine. The residue was taken in 10:1methanol-water (200 mL) and boiled overnight. The mixture wasconcentrated, and the residue co-evaporated with ethanol.Crystallization from acetone-heptane yielded compound 19 (3.6 g, 66.2%);m.p. 145°-147° C.; α!_(D) +6.4° (c 1.25, chloroform), t.l.c. (9:1chloroform-methanol). ³ C NMR (CD₃ OD): δ111.67 C(CH₃)₂ !, 104.73 (C-1,C-1'), 81.57, 81.41 (C-3', C-4), 76.90, 75.91, 75.63, 75.40, 75.02 (C-2,C-2', C-4', C-5, C-5'), 71.54 OCH₂ (CH₂)6-), 62.98, 62.43 (C-6, C-6'),29.04, 27.14 (CH₃)₂ C!, 31.66-24.31 CH₂ (CH₂)₆ !, and 15.07 (CH₃);negative LSIMS: 493.5 (M-H)⁻, positive LSIMS: 517.6 (M+Na)⁺.

Method (b): A mixture of 18 (5 g) and 4-toluenesulfonic acid (1 g), inacetone (500 mL) was boiled for about 4 h. The acid was neutralized bythe addition of triethylamine, and the mixture concentrated. Addition ofacetone-heptane caused the crystalliza-tion of 19 (4 g, 73.5%).

EXAMPLE 17 Preparation of Octyl2,6-di-O-benzoyl-4-O(2,6-di-O-benzoyl-3,4-O-isopropylidene-β-galactopyranosyl)-β-D-glucopyranoside(20)

A solution of benzoyl chloride (8.1 mL, 67.5 mmol) in pyridine (35 mL)was added dropwise to a solution of 19 (7.5 g, 15.2 mmol) in pyridine(140 mL) at -45° C. and the mixture was stirred for 3-4 h at -40°-45° C.The mixture was poured into ice-water and extracted with dichloromethane(3×50 ml). The dichloromethane solution was successively washed withwater, ice-cold 5% aqueous H₂ SO₄, aqueous NaHCO₃, water, dried (Na₂SO₄), and concentrated. The crude product was crystallized frommethanol-2-propanol (3:1 v/v) to give the desired tetrabenzoate 20, (8.2g, 59.4%). An analytical sample was obtained by recrystallization fromdichloromethane- methanol, m.p. 133°-134.5° C.; α!_(D) +16.9° (c 0.9,chloroform), t.l.c. (8.5:1.5 toluene-ethyl acetate). ¹ H NMR (CDCl₃):δ8.20-7.10 (m, 20H, arom.), 5.37 (t, 1H, J 7.8 Hz, H-2'), 5.22 (dd, 1H,J 8.2 and 9.5 Hz, H-2, 4.67 (d, 1H, J 8.2 Hz, H-1'), 4.53 (d, 1H, J 8.1Hz, H-1), and 1.65 and 1.35 2s, 3H, each, C(CH₃)₂ !; ¹³ C NMR (CDCl₃):δ166.55-165.27 (4×PhCO), 111.24 C(CH₃)₂ !, 101.51, 100.95 (C-1, C-1'),82.48 (C-4), 77.03 (C-3'), 73.45 (C-4'), 73.02, 72.89, 72.07 and 72.02(C-2, C-2', -3, C-5, C-5'), 70.02 CH₂ (CH₂)₆, 63.69, 62.70 (C-6, C-6'),31.64, 29.33, 29.14, 29.05, 25.71, and 22.55 (CH₂)₆ CH₃ !, 27.62, 26.27(CH₃)₂ C!, and 14.03 (CH₃); negative LSIMS: 1063.2 (M-H+mNBA)⁻, 956.2(M+NO₂)⁻.

EXAMPLE 18 Preparation of Octyl2,6-di-O-benzoyl-3-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-4-O-(2,6-di-O-benzoyl-3,4-O-isopropylidene-β-D-galactopyranosyl)-β-D-glucopyranoside(21)

A mixture of compound 20 (7 g, 7.7 mmol), methyl2,3,4-tri-O-benzyl-1-thio-L-fucopyranoside (8, 6.5 g, 14.1 mmol) andpowdered 4 A molecular sieves (10 g), in 5:1dichloroethane-N,N-dimethyl-formamide (150 mL), protected from moisture,was stirred for 2 h at room temperature. Cupric bromide (4 g, 18 mmol)and tetrabutyl-ammonium bromide (2 g, 6.2 mmol) were added and themixture was stirred overnight at room temperature. More of the donor 8(2 g, 4.3 mmol, in 12 mL of 5:1 dichloroethane-N,N-dimethylformamide)and cupric bromide (1.2 g, 2.6 mmol) were added, and the stirring wascontinued for 16 h at room temperature. The mixture was filtered overcelite and the solids were thoroughly washed with dichloromethane. Thefiltrate and washings were combined and stirred for 15 min with 10% NaEDTA solution. The organic solution was separated, and this process wasrepeated (2×10% Na EDTA followed by 2×5% Na EDTA solution). The organicphase was washed with water, dried (Na₂ SO₄), and concentrated to athick syrup under diminished pressure. The residue was crystallized fromether-heptane to yield 21, (8.5 g, 83%). An analytically pure sample of21 was obtained by crystallization from dichloromethane-ether, m.p.152°-153° C.; α!_(D) +2.5° (C 1.1, chloroform), t.l.c. (8.5:1.5toluene-ethyl acetate). ¹³ C NMR (CDCl₃): , δ166.24, 166.05, 164.71,164.52 (4×PhCO), 110.83 C(CH₃)₂ !, 101.43, 100.24 (C-1, C-1'), 97.38(C-1 fuc), 74.89, 72.63, 72.43 (3×CH₂ Ph), 70.11 OCH₂ (CH₂)₆₋ !, 62.58,62.48 (C-6, C-6'), 31.67-22.56 (CH₂)₆ CH₃ !, 27.75, 26.25 (CH₃)₂ C!,16.90 (C-6 fuc), and 14.05 (CH₃); negative LSIMS: 1480.1 (M-H+mNBA)⁻,positive LSIMS: 1349.9 (M+Na)+.

EXAMPLE 19 Preparation of Octyl2,6-di-O-benzoyl-3-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-4-O-(2,6-di-O-benzoyl-β-D-galactopyranosyl)-β-D-glucopyranoside(22)

A solution of 21 (8 g) in chloroform (300 mL), containingtrifluoroacetic acid (18 mL) and water (3-4 mL) was stirred vigorouslyfor 10 h at room temperature, the reaction being monitored by t.l.c.(19:1 or 9:1 chloroform-acetone), which indicated the progressivediminishing of 21 with a simultaneous increase in the slower-migratingdiol 22. Some removal of the fucopyranosyl residue also occurred asevidenced by the presence in t.l.c. of a spot migrating marginallyfaster than 22 (chromato-graphic mobility identical to that of tribenzylfucose), and a slower migrating product (presumably the lactosidetriol). T.l.c. also revealed the presence of a small proportion ofunchanged 21, but the reaction was terminated to avoid excessivedefucosylation. The mixture was poured into ice-cold, saturated aqueousNaHCO₃ solution and stirred for 15 min. The chloroform solution wasseparated and washed again with NaHCO₃ solution, followed by water,dried (Na₂ SO₄), and concentrated. The residue was purified using asilica gel column (5-20% ethyl acetate in toluene) to yield unreacted 21(0,8 g), tribenzyl fucose, and 22 (5.4 g, 69.6%) as a foam; α!_(D)-20.2° (c 1.1, chloroform). ¹³ C NMR (CDCl₃): δ167.22-165.11 (4×PhCO),102.09, 100.60 (C-1, C-1'), 98.20 (C-1 fuc), 79.56, 79.07 (C-3, C-4),75.77, 73.16, 72.98 (3×CH₂ Ph), 70.65 OCH₂ (CH₂)₆ !, 68.41, 67.12 (C-6,C-6'), 32.27 -23.16 ( OCH₂ (CH₂)₆ !, 17.17 (C-6 fuc), and 14.65 (CH₃).

EXAMPLE 20 Preparation of Octyl2,6-di-O-benzoyl-4-O-(4-O-acetyl-2,6-di-O-benzoyl-β-D-galacto-pyranosyl)-3-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-β-D-glucopyranoside(23)

Compound 22 (5 g) was dissolved a 1:1 mixture of benzene andtriethylorthoacetate (110 mL), containing 4-toluenesulfonic acid (0.2g), and the mixture was stirred for 1 h at room temperature. The acidwas neutralized with triethylamine, and the mixture evaporated todryness. The residue was dissolved in 80% aqueous acetic acid (75 mL)and stirred for 40 min at room temperature. The acetic acid wasevaporated under diminished pressure and the last traces were removed byco-evaporation with toluene to yield 23 (4.7 g, 91.3%); α!_(D), -4.5° (c0.8, chloroform), t.l.c. (5:1 ethyl acetate-toluene). ¹³ C NMR (CDCl₃):δ170.98 (COCH₃), 166.75, 166.33, 166.18, 165.07 (4×PhCO), 102.03, 101.08(C-1, C-1'), 98.16 (C-1 fuc), 80.07, 78.23 (C-3, C-4), 74.69, 73.53,73.24 (3×PhCH₂), 70.66 OCH₂ (CH₂)₆ !, 63.23, 61.42 (C-6, C-6'),32.25-23.14 (CH₂)₆ CH₃ !, 21.20 (COCH₃), 17.49 (C-6 fuc), and 14.63(CH₃).

EXAMPLE 21 Preparation of Octyl2,6-di-O-benzoyl-3-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-4-O-(sodium4-O-acetyl-2,6-di-O-benzoyl-β-D-galactopyranosyl3-sulfate)-β-glucopyranoside (24)

A mixture of 23 (4.5 g) and sulfur trioxide-pyridine complex (4.5 g) indry pyridine (65 mL) was stirred for approximately 40 min at 55°-60° C.After cooling to room temperature, methanol (5 mL) was added and themixture stirred for 20 min, concentrated and the residue co-evaporatedwith toluene. The residue was purified on a silica gel column (19:1followed 9:1 chloroform-methanol). On evaporation of the fractionscorresponding to the product, the residue so obtained was dissolved in1:1 chloroform-methanol and stirred with Amberlite IR 120 (Na+)cation-exchange resin for 1 h at room temperature. The resin wasfiltered off and washed with chloroform-methanol and the solution wasevaporated to yield 24 (3.2 g, 84.7%) as an amorphous solid; α!_(D)+5.3° (C 1.1, chloroform-methanol 1:1 v/v), t.l.c. (9:1chloroform-methanol).

EXAMPLE 22 Preparation of Octyl O-α-L-fucopyranosyl-(1→3-O- sodiumβ-D-galactopyranosyl 3-sulfate-(1→4)!-β-D-glucopyraneside (26)

Compound 24 (4.4 g) in methanol (100 mL), containing a catalytic amountof sodium methoxide, was stirred overnight at 45°-50° C. (t.l.c. 6:2:1ethyl acetate-2-propanol-water). The mixture was cooled to roomtemperature, neutralized (pH paper) with Amberlite IR 120 (H⁺)cation-exchange resin, filtered directly into a flask containingAmberlite IR 120 (Na⁺) cation-exchange resin, and stirred for 45 min atroom temperature. The resin was filtered and washed with methanol, thefiltrate and washings combined and concentrated. Several portions ofhexane were added to, and decanted from the residue to yield thepartially protected intermediate 25 (2.7 g, 90%); α!_(D), -54.1° (c 0.8,methanol), t.l.c. (6:2:1 ethyl acetate-2-propanol-water); positiveLSMIS: 995.6 (M+Na)+, negative LSIMS: 949.7 (M-Na).

A solution of 25 (2.6 g) in 4:1 methanol-water (100 mL), containing 10%palladium-on-carbon (2.6 g) was stirred overnight at room temperatureunder a hydrogen atmosphere. The mixture was filtered over celite,directly onto Amberlite IR 120 (Na⁺) cation exchange resin, and thesolids thoroughly washed with aqueous methanol. The mixture was stirredwith the resin for about 1 h, filtered and concentrated. Examination ofthis material by mass spectrometry indicated that it was contaminatedwith a small proportion of a compound carrying a benzoyl group, asevidenced by an ion with a mass of 783 (M-Na+Bz). This material wasagain subjected to Zemplen trans-esterification exactly asaforedescribed. After the usual processing, it was purified on a silicagel column (13:6:1 chloroform-methanol-water). Fractions correspondingto the product were pooled and concentrated to yield a residue, whichwas redissolved in water, filtered (0.2 μM Cellulose acetate syringefilter) and lyophilized to yield 26 (1.68 g, 89.8%), as a white fluffysolid; α!_(D) -58.6° (C0.7, methanol), t.l.c. (13:6:1chloroform-methanol-water); negative LSIMS: 679.6 (M-Na)⁻, 701.7 (M-H)⁻.

EXAMPLE 23 Preparation of OctylO-(2,6-di-O-benzoyl-3.4-O-isopropylidene-β-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tri-O-benzoyl-β-D-glucopyranoside(27)

A solution of 19 (2.5 g, 5 mmol) in pyridine (50 mL), was treated withbenzoyl chloride (4.5 mL, 37.5 mmol) and the mixture stirred overnightat room temperature. The mixture was poured into ice-water and extractedwith dichloromethane (3×30 mL). The combined organic layer was washedwith water, cold 5% H₂ SO₄, cold saturated NaHCO₃, and water, dried, andconcentrated to a syrup, which crystallized from methanol to yield 27(4.7 g, 91.6%); m.p. 156°-157° C.; α!_(D) +40.5° (c 1.3, chloroform),t.l.c. (8.5:1.5 toluene-ethyl acetate). ¹ H NMR (CDCl₃): δ8.40-7.20 (m,25H, arom.), 5.72 (t, 1H, J 9.4 Hz, H-3), 5.42 (dd, 1H, J 7.9 and 9.7Hz, H-2'), 5.14 (t, 1H, J 7.3 Hz, H-2'), 4.64 (d, 1H, J 7.9 Hz, H-1'),4.58 (d, 1H, J 7.7 Hz, H-1), 1.52, 1.24 (s, 3H each, (CH₃)₂ C!, and 0.8t, 3H, J 7.1 Hz, CH₃ (CH₂)₆ !; ¹³ C NMR (CDCl₃): δ166.57, 166.49,166.24, 165.76, 165.49 (5×PhCO), 111.45 C(CH₃)₂ !, 101.74, 100.74 (C-1,C-1'), 77.68 (C-4), 76.04-71.93 (C-2,2',C-3,3', C-4', C-5,5'), 70.90OCH₂ (CH₂)₆ !, 63.43, 63.28 (C-6, C-6'), 32.25-23.16 CH₂)₆ CH₃ !, 28.01,26.74 C(CH₃)₂ !, and 14.65 (CH₃); negative LSIMS: 1167.4 (M+mNBA)⁻,positive LSIMS: 1037.0 (M+Na)⁺.

EXAMPLE 24 Preparation of OctylO-(2,6-di-O-benzoyl-β-D-galactopyranosyl)-(1→4)-2,3,6-tri-O-benzoyl-β-glucopyranoside(28)

A solution of compound 27 (4.5 g) in chloroform (200 mL) was treatedwith trifluoroacetic acid (25 mL) and water (3 mL), and the mixturestirred for 2 h at room temperature. The mixture was washed withice-cold, saturated NaHCO₃, and water, dried and concentrated to yield28 (4.15 g, 96%), amorphous; α!_(D) +38.60 (c 1.6, chloroform), t.l.c.(4:1 toluene-ethyl acetate). ¹³ C NMR (CDCl₃): δ166.69-165.78 (5×PhCO),101.75, 101.51 (C-1, C-1'), 77.06 (C-4), 70.86 OCH₂ (CH₂)₆ !, 63.37,62.86 (C-6, C-6'), 32.26-23.16 (CH₂)₆ CH₃ !, and 14.66 (CH₃); negativeLSIMS: 973.3 (M-H)⁻, 1019.9 (M+NO2)⁻, 1127.1 (M+mNBA)⁻, positive LSIMS:997.0 (M+Na)⁺.

EXAMPLE 25 Preparation of OctylO-(4-O-acetyl-2,6-di-O-benzoyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-benzoyl-β-D-glucopyranoside(29)

A solution of 28 (4 g) in a 1:1 mixture of benzene andtriethylorthoacetate (100 mL), containing 4-toluenesulfonic acid (200mg), was stirred for 1 h at room temperature. The acid was neutralizedwith triethylamine and the mixture concentrated, dissolved in 80%aqueous acetic acid and stirred for 40 min at room temperature. Theacetic acid was evaporated in vacuo, and co-evaporated with toluene toyield 29 (4 g, 95.9%); α!_(D) +17.85° (C 1.35, chloroform). ¹³ C NMR(CDCl₃): δ171.25 (CH₃ CO), 166.85-165.78 (5×PhCO), 101.73, 101.06 (C-1,C-1'), 76.34 (C-4), 70.92 OCH₂ -(CH₂)₆ !, 63.34, 61.96 (C-6, C-6'),32.25-21.19 (CH₂)₆ CH₃ !, and 14.63 (CH₃); Negative LSIMS: 1169.0(M+mNBA)-, 1038.8 (M+Na)+.

EXAMPLE 26 Preparation of Octyl 4-O-(sodium β-D-galactopyranosyl3-sulfate)-β-glucopyranoside(31)

A mixture of 29 (3.8 g) and sulfurtrioxide-pyridine complex (3.8 g) inpyridine (60 mL) was stirred for about 40 min at 55°-60° C. The mixturewas cooled to room temperature, methanol (5 mL) was added and themixture stirred for 20 min at room temperature. It was concentrated andco-evaporated with toluene. The residue was purified on a silica gelcolumn (19:1 and 9:1 (v/v) chloroform-methanol) to yield 30 (3.5 g,83.3%); negative LSIMS: 1095.2 (M-Na)⁻.

Compound 30 was dissolved in methanol (100 mL) containing a catalyticamount of sodium methoxide and the mixture stirred overnight at about45°-50° C. After processing in the usual manner, the residue waspurified on a silica gel column (13:6:1 chloroform-methanol-water) toyield 31 (1.65 g, 94.8%); α!_(D) -4.5° (c 1.5, methanol); NegativeLSIMS: 533.4 (M+Na)-, 555.4 (M-H)-.

EXAMPLE 27 Selectin Ligand Properties of Lactose Derivatives

Compounds 13a, 13b, 26 and 31 were tested for their capacity to bind toE, L and P selectin. The ELISA assay used consists of evaporating 2,3sLex glycolipid, at 25 picomoles per well, onto microtiter wells, andthen washing the excess off with water. The wells are blocked with 5%BSA at room temperature for an hour and then washed with PBS containing1 mM Ca. While the plate is being blocked, biotin labelled goat F(ab')₂IgG (Fc specific) and streptavidinalkaline phosphatase diluted 1:1500 in1% BSA-PBS (1 mM Ca) are combined with either the E, L or P Selectin-IgGchimera (L91-10) at 200 ng/mL and incubated at 37° C. for 15 minutes toallow a complex to form. This provides a soluble "multivalent" receptor.Compounds 13a and 13b were added at final concentrations ranging from1.5 to 5.0 mM to the soluble receptor and allowed to react at 37° C. for45 minutes. The solutions were then placed in the microtiter wells thathad been washed after being blocked, and the plates incubated at 37° C.for 45 minutes to allow the soluble receptor to bind to the knownnatural ligand, 2,3 sLex glycolipid. The positive control was the signalproduced by soluble "multivalent" receptor reacted with only the ligandevaporated to the microtiter well. This was considered "100% binding."The signal produced by receptor previously reacted with inhibitor isdivided by the signal produced by the positive control, multiplied by100, to calculate % receptor bound in the presence of the inhibitor. Thereciprocal of this is % inhibition.

It is apparent from Table 1 that compounds 13a, 13b and 26 inhibitbinding of E selectin to 2,3 sLex glycolipid. Over the threeconcentrations tested 13b was the better inhibitor with the greatestdifference apparent at 5ram concentration. At this concentration 13bshowed 82.5% inhibition compared to 48% for 13a.

                  TABLE 1                                                         ______________________________________                                        INHIBITION OF E-SELECTIN BINDING TO sLeX                                      COMPOUND      CONC. (mM) % INHIBITION                                         ______________________________________                                        13a           1.25       30                                                                 2.5        34                                                                 5.0        48                                                   13b           1.25       48.5                                                               2.5        45.4                                                               5.0        82.5                                                 26            0.5        0                                                                  1.0        30                                                                 2.0        50                                                                 4.0        70                                                   31            0.5        0                                                                  1.0        0                                                                  2.0        0                                                                  4.0        0                                                    ______________________________________                                    

It is apparent from Table 2 that both compounds 13a and 13b also inhibitbinding of L selectin to 2,3 sLex glycotipid. However, the differencehere was considerably greater than the difference in % inhibition forbinding to E selectin. For example, at 1.25 mM, 13b surprisingly showed90% inhibition. 100% inhibition was observed at 2 mM and 5 mM. In markedcontrast, 13b displayed only 13% inhibition at 1.25 mM and a maximuminhibition of 47% at 5 mM. Compound 26 displayed 30% inhibition at allthe concentrations tested. Compound 31 is inactive in the inhibition ofE- and L-selectin binding to sLex.

                  TABLE 2                                                         ______________________________________                                        INHIBITION OF L-SELECTIN BINDING TO sLeX                                      COMPOUND      CONC. (mM) % INHIBITION                                         ______________________________________                                        13a            1.25      13                                                                 2.5        27                                                                 5.0        47                                                   13b            1.25      90                                                                 2.5        100                                                                5.0        100                                                  26            0.5         0                                                                 1.0        30                                                                 2.0        30                                                                 4.0        30                                                   31            0.5         0                                                                 1.0         0                                                                 2.0         0                                                                 4.0         0                                                   ______________________________________                                    

Table 3 indicates that compound 26 is a better inhibitor of P selectin(as compared to L-selectin) binding to 2,3 sLex glycolipid.

                  TABLE 3                                                         ______________________________________                                        INHIBITION OF P-SELECTIN BINDING TO sLeX                                      COMPOUND      CONC (mM)  % INHIBITION                                         ______________________________________                                        26            0.5         0                                                                 1.0        20                                                                 2.0        40                                                                 4.0        45                                                   ______________________________________                                    

EXAMPLE 28 Acute Lung Injury Assay

Experiments were done to determine the effectiveness of compounds 13b or31 in their ability to reduce neutrophil-dependent injury to the lungendothelium and alveolar epithelium following acid aspiration injury.

Female New Zealand White rabbits (1 each/group, approx. 2 KG each) wereanesthetized with halothane and ventilated with positive pressureventilation supplemented with oxygen. Vascular catheters were placed inthe carotid artery, into the internal jugular vein, and a tracheostomywas made for positive pressure ventilation. A low pH solution (HCl, pH1.5) was installed in Ringer's lactate (osmolality=approximately 100) ata dose of 3 ml/kg into the trachea to stimulate a gastric aspirationinduced lung injury. Compound 13b or 31 were injected (10 mg/kg/hr IV) 5minutes prior to intratracheal instillation of the low pH solutionscontinued by hourly injections until the end of the experiment.Appropriate controls were used. An intravascular as well as anintra-alveolar radiolabelled protein tracer was injected to quantifylung endothelial and alveolar epithelial protein permeability. Arterialblood gases, systemic blood pressure and airways were monitored. At theend of 6 hours the lungs were removed and alveolar fluid was sampledfrom both lungs in order to measure the concentration of native proteinas well as radiolabelled proteins in the airspaces to calculate lungvascular and lung epithelial permeability. Also, one lung was lavaged inorder to count the neutrophils that are present in the airspaces of thelungs. Extravascular lung water measurements was done on the lung whichwas not lavaged. Histological samples were taken from selected portionsof the lung.

Animals treated with either compound 13b or 31 showed a decrease inAlveolar-arterial blood oxygen gradient as compared to the controlanimals. FIGS. 1 and 2 show the effect of compounds 13b and 31respectively on rabbits in the acute lung injury model.

It is noteworthy that compound 31 (see Example 27) was inactive in vitroin inhibition of E- and L-selectin binding to sLex, but effectivelyreduced neutrophil-dependent injury to the lung endothelium and alveolarepithelium following acid aspiration injury in the acute lung injurymodel. It is possible that compound 31 is fucosylated in vivo, therebyexplaining the positive activity of compound 31 in the acute lung injurymodel.

EXAMPLE 29 Reperfusion Injury Assay

Experiments were done to determine the effectiveness of compound 13b indecreasing adhesion of human neutrophils in the rabbit isolated head.Addition of the human plasma to the rabbit isolated head results inactivation of the complement components found within the plasma, whichin turn promotes an increase in the neutrophil accumulation. This modelis used to determine the effect of lactose derivatives on inhibitingcomplement-induced neutrophil adhesion.

Hearts from New Zealand White rabbits were excised, mounted on amodified Langendorff apparatus and perfused with Krebs-Heinseleitbuffer. Cardiac functional parameters were monitored upon a Grass Model79D polygraph machine. 4% normal human plasma (NHP) was added to therecirculating buffer. Ten minutes after the addition of the plasma, 13b(0.1 mg/ml) was added to the perfusate. After 15 minutes of perfusionwith the plasma, 51-chromium labelled human neutrophils (1×10⁵ /ml) wereadded to the perfusate and allowed to recirculate for an additional 15minutes. At the end of this time the hearts were washed with freshbuffer to remove non-specifically bound neutrophils, dried and countedin a well type gamma-counter. A concentration response curve wasgenerated using concentrations of 0.001, 0.01 and 0.1 mg/ml. Six heartswere used for each of these concentrations.

Table 4 lists the results, expressed as the percent inhibition ofneutrophil accumulation. The results of the concentration-response studyare shown in FIG. 3. These results are expressed as the number ofradiolabelled human neutrophils/mg of dry weight of the heart.

It should be noted that the number of neutrophils seen with the 0.001mg/ml concentration of compound 13b is similar to that of the control.Compound 13b inhibited neutrophil adhesion in a concentration-dependentmanner with the most significant degree of inhibition using the 0.1mg/ml dose. These data provide evidence that compound 13b was successfulin decreasing neutrophil adhesion in this model. It should also be notedthat the greatest degree of inhibition seen using pharmacologicalagents, including a number of peptides derived form P-selectin andantibodies directed against P-selectin and the CD11b/CD18 complex (Ma,Xin-liang, et al., Circulation (1993) 88-2:649), has been 40%. Compound13b provides a degree of inhibition similar to any of thepharmacological agents tested thus far.

Based on the above results, it is apparent that the compounds of theinvention are useful for treating diseases, preferably diseases thathave an inflammatory component, Adult Respiratory Distress Syndrome(ARDS), ischemia and reperfusion injury, including strokes, mesentericand peripheral vascular disease, organ transplantation, and circulatoryshock (in this case many organs might be damaged following restorationof blood flow).

                  TABLE 4                                                         ______________________________________                                        Compound     % Neutrophil Inhibition                                          ______________________________________                                        13b          35                                                               ______________________________________                                    

    __________________________________________________________________________    SEQUENCE LISTING                                                              (1) GENERAL INFORMATION:                                                      (iii) NUMBER OF SEQUENCES: 2                                                  (2) INFORMATION FOR SEQ ID NO:1:                                              (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 31 base pairs                                                     (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                          (ii) MOLECULE TYPE: DNA (genomic)                                             (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:                                       GGTGCGGCCGCGGCCAGAGACCCGAGGAGAG31                                             (2) INFORMATION FOR SEQ ID NO:2:                                              (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 29 base pairs                                                     (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                          (ii) MOLECULE TYPE: DNA (genomic)                                             (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:                                       GGTGTCGACCCCACCTGAGAGATCCTGTG29                                               __________________________________________________________________________

We claim:
 1. A method of treatment of a selectin-mediated disorder in apatient in need thereof comprising administering to the patient atherapeutically effective amount of a compound having the followingstructural formula ##STR8## wherein each R¹ is independently H or loweralkyl (1-4C); R² is H, a lower alkyl group (1-4C), a higher alkyl group(5-15C), alkylaryl or an additional saccharide residue;R³ is anegatively charged moiety selected from the group consisting of --SO₄ ²⁻and --PO₄ ²⁻ ; Y is H, OH or lower alkyl (1-4C); and X is H or --CHR⁴(CHOR¹)₂ CHR⁵ OR¹ wherein R⁴ and R⁵ are each independently H, loweralkyl (1-4C), or taken together result in a five- or six-membered ringoptionally containing a heteroatom selected from the group consisting ofO, S, and NR¹ ; said five- or six-membered ring optionally substitutedwith one substituent selected from the group consisting of R¹ CH₂OR¹,OR¹,OOCR¹, NR₂ ¹, NHCOR¹, and SR¹ ;and salts thereof.
 2. A method asin claim 1 wherein the selectin-mediated disorder is selected from thegroup consisting of inflammation, autoimmune disease, rheumatoidarthritis, ischemia and reperfusion injury, shock and cancer.
 3. Amethod as in claim 1 wherein all R¹ are H.
 4. A method as in claim 3wherein R² is H.
 5. A method as in claim 4 wherein X is H and R³ is--SO₄ ²⁻.
 6. A method as in claim 4 wherein X is a fucosyl residue.
 7. Amethod as in claim 6 wherein R³ is --SO₄ ²⁻.
 8. A method as in claim 1wherein X is selected from the group consistingof:6-methyl-3,4,5-trihydroxypyran-2-yl,6-acetyl-3,4,5,trihydroxypyran-2-yl,6-propylamido-3,4,5,trihydroxypyran-2-yl,6-propylamido-2,3,4-trimethoxypyran-2-yl,6-ethyl-2,3-dihydroxy-4-methoxypyran-2-yl,6-N-ethylamino-2-hydroxy-3,4-ethoxypyran-2-yl,3,4,5-tri-n-propyloxypyran-2-yl, 3.4,5-trihydroxypyran-2-yl,2,3,4-trimethoxyfuran-2-yl,2,3-dihydroxy-4-methoxyfuran-2-yl, 2-hydroxy-3,4-ethoxyfuran-2-yl,3,4,5-tri-n-propyloxyfuran-2-yl, 3,4,5-trihydroxyfuran-2-yl, or2,3,4-trihydroxybenzoyl.
 9. A method as in claim 1 wherein all R¹ are Hand R² is --CH₂ (CH₂)₆ CH₃.
 10. A method as in claim 9 wherein X is Hand R³ is --SO₄ ²⁻.
 11. A method as in claim 9 wherein X is a fucosylresidue and R³ is --SO₄ ²⁻.
 12. A method as in claim 1 wherein X is afucosyl residue.
 13. A method as in claim 12 wherein R³ is --SO.sub.²⁻.14. A method of treating inflammation in a patient in need thereofcomprising administering to the patient a therapeutically effectiveamount of a compound having the following structural formula: ##STR9##wherein each R¹ is independently H or lower alkyl (1-4C); R² is H, alower alkyl group (1-4C), a higher alkyl group (5-15C), alkylaryl or anadditional saccharide residue;R³ is a negatively charged moiety selectedfrom the group consisting of --SO₄ ²⁻ and --PO₄ ²⁻ ; Y is H, OH or loweralkyl (1-4C); and X is H, --CHR⁴ (CHOR¹)₂ CHR⁵ OR¹ wherein R⁴ and R⁵ areeach independently H, lower alkyl (1-4C),6-methyl-3,4,5-trihydroxypyran-2-yl,6-acetyl-3,4,5,trihydroxypyran-2-yl,6-propylamido-3,4,5,trihydroxypyran-2-yl,6-propylamido-2,3,4-trimethoxypyran-2-yl,6-ethyl-2,3-dihydroxy-4-methoxypyran-2-yl,6-N-ethylamino-2-hydroxy-3,4-ethoxypyran-2-yl,3,4,5-tri-n-propyloxypyran-2-yl, 3,4,5-trihydroxypyran-2-yl,2,3,4-trimethoxyfuran-2-yl, 2,3-dihydroxy-4-methoxyfuran-2-yl,2-hydroxy-3,4-ethoxyfuran-2-yl, 3,4,5-tri-n-propyloxyfuran-2-yl,3,4,5-trihydroxyfuran-2-yl, or 2,3,4-trihydroxybenzoyl;and saltsthereof.
 15. A method as in claim 14 wherein all R¹ are H, R² is H, R³is --SO₄ ²⁻ and X is a fucosyl residue.
 16. A method as in claim 14wherein all R¹ are H, R² is --CH₂ (CH₂)₆ CH₃, R³ is --SO₄ ²⁻ and X is Hor a fucosyl residue.
 17. A method of inhibiting selectin receptorbinding to a sialyl Lewis X oligosaccharide comprising administering toa patient in need thereof a compound having the following structuralformula: ##STR10## wherein each R¹ is independently H or lower alkyl(1-4C); R² is H, a lower alkyl group (1-4C), a higher alkyl group(5-15C), alkylaryl or an additional saccharide residue;R³ is anegatively charged moiety selected from the group consisting of --SO₄ ²⁻and --PO₄ ²⁻. Y is H, OH or lower alkyl (1-4C); and X is H, --CHR⁴(CHOR¹)₂ CHR⁵ OR¹ wherein R⁴ and R⁵ are each independently H, loweralkyl (1-4C), 6-methyl-3,4,5-trihydroxypyran-2-yl,6-acetyl-3,4,5,trihydroxypyran-2-yl,6-propylamido-3,4,5,trihydroxypyran-2-yl,6-propylamido-2,3,4-trimethoxypyran-2-yl,6-ethyl-2,3-dihydroxy-4-methoxypyran-2-yl,6-N-ethylamino-2-hydroxy-3,4-ethoxypyran-2-yl,3,4,5-tri-n-propyloxypyran-2-yl, 3,4,5-trihydroxypyran-2-yl,2,3,4-trimethoxyfuran-2-yl, 2,3-dihydroxy-4-methoxyfuran-2-yl,2-hydroxy-3,4-ethoxyfuran-2-yl, 3,4,5-tri-n-propyloxyfuran-2-yl,3,4,5-trihydroxyfuran-2-yl, or 2,3,4-trihydroxybenzoyl;and saltsthereof.
 18. A method as in claim 17 wherein all R¹ are H.
 19. A methodas in claim 18 wherein R³ is --SO₄ ²⁻.
 20. A method as in claim 19wherein X is H or a fucosyl residue and R² is H or --CH₂ (CH₂)₆ CH₃.